ClinicalTrials.gg
CompletedNCT05249543Updated Nov 13, 2026

Transdiagnostic Versus Diagnosis-specific Cognitive-behavioral Therapy

An interventional study of Unified protocol and Diagnosis-specific cognitive-behavioral therapy in Panic Disorder, Generalized Anxiety Disorder and Social Anxiety Disorder, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Panic Disorder with a site in Sweden — 4 open to participants now, 5 under way, none of them phase 3. Panic Disorder · Sweden.

Enrollment
9th of 13
67 · median 113
Started
2022
with 1 other
No phase
12 of 14
4 open now
Registered
7th of 14
by date
Lead sponsor
6 of 14
Karolinska Institutet

Among the 14 studies in Panic Disorder with a site in Sweden, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 7th registered.

Panic Disorder

270 studies on the registry are indexed under Panic Disorder; 37 are open to participants now.

Browse Panic Disorder studies →

Open to participants now

4 of the 14 studies in Panic Disorder with a site in Sweden are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 24 Panic Disorder studies recruiting now, 8 (33%) set no upper age limit and 15 (63%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Panic Disorder with a site in Sweden, or all of them as a file.
02

Study summary

The primary aim of the pilot study is to investigate the feasibility of conducting a randomized controlled trial (RCT) comparing the effects of transdiagnostic and diagnosis-specific cognitive-behavioral therapy (CBT) for patients with anxiety disorders in routine psychiatric outpatient care in Stockholm, Sweden. It is hypothesized that an RCT is feasible in terms of recruitment, retention, therapist competence and adherence to treatments, and that the treatments are well received by participants.

Read the detailed description

Aim

The primary aim of the pilot study is to investigate the feasibility of conducting an RCT comparing the the effects of two types of protocol-based individual CBT for patients with anxiety disorders: transdiagnostic CBT using the unified protocol (UP) and diagnosis-specific CBT using single disorder protocols (SDP). The aim of a future RCT is to replicate the only equivalence RCT of the UP and SDPs for patients with anxiety disorders (Barlow et al., 2017). Feasibility is investigated in terms of a) recruitment of participants across diagnoses, b) retention of participants and data loss at post treatment, c) therapist competence in and adherence to the UP and SDPs, d) treatment credibility and expectancy of improvement and treatment satisfaction, and e) adverse effects. A secondary aim is to explore the effects of the treatments in terms of a) clinical severity of diagnosis, b) anxiety and depressive symptoms, and c) functional impairment and quality of life.

Design

Randomized controlled design by which the UP is compared to SDPs. Randomization of participants is conduced using a 1:1 ratio. A sequence of random numbers are generated per therapist by an independent assistant using an online random number service. The study is conducted in routine psychiatric outpatient care at clinics in Stockholm, Sweden.

Participants

For inclusion and exclusion criteria, see other data elements. To investigate the feasibility of an RCT and expecting a dropout rate of 20% consistent with prior research of CBT for anxiety disorders, we believe that 76 participants is an appropriate number. In addition, prior to recruitment of participants for treatment, 16 participants (four per therapist) are recruited for assessment of therapist competence and adherence to the UP and SDPs. Therapists are psychologists with training in SDPs. As their competence and adherence are assessed, therapists are also participants in the study.

Assessment

Diagnostic assessment is conducted using the Mini International Neuropsychiatric Interview (Sheehan et al., 1998). Clinical severity of diagnosis is assessed using the Clinical Severity Rating (CSR; Brown \& Barlow, 2014), which is rated 0-8 with 4 and above indicating meeting a diagnosis. For feasibility and treatment effects measures, see other data elements.

Feasibility measures

Participant recruitment. We expect to be able to recruit at least seven participants per month with four therapists.

Attrition. A common attrition rate in studies of CBT for anxiety disorders is 20%. I the 2017 equivalence RCT by Barlow and colleagues, 88% of participants in the UP condition and 69% of participants in the SDP condition completed treatment (defined as attending at least 75% of sessions). Thus, we expect an attrition rate of 20% at the most in respective treatment condition.

Competence in and adherence to the UP and SDPs. Prior to participant recruitment, therapists record treatment sessions on audio with participants who are not treated in the study and these audio-recordings are coded by independent raters to assess therapist competence and adherence to the UP and SDPs. Assessment of competence in and adherence to the UP is conducted using the UP Adherence and Competence Scale (Boswell et al., 2013). This assessment is included in the UP training of therapists and is conducted for all treatment modules used with one participant exclusively recruited for training purposes. Assessment of competence in diagnosis-specific CBT is conducted using the Cognitive Therapy Scale-Revised (Blackburn et al., 2001), and adherence using the Adherence to Cognitive-Behavioral Therapy Scale (Bergvall \& Bohman, 2018). For diagnosis-specific CBT, estimates of competence and adherence are based on three treatment sessions with three different participants per therapist recorded on audio and coded by independent raters. These three participants are not treated in the study. As for participants treated in the study, participants who are recruited only for training and assessment purposes provide written informed consent to take part in the study.

Perceptions of the UP and SDPs and study procedures. Both patients and therapists respond to surveys exploring the provision or receipt of the treatments. Patients also respond to questions covering study procedures, including the assessment procedure and number of measures at different assessment points.

Treatment credibility and expectancy of improvement is assessed at session 2 using the Credibility/Expectancy Questionnaire (Devilly \& Borkovec, 2000). Treatment satisfaction is assessed at post treatment using the Client Satisfaction Questionnaire (Attkison \& Greenfield, 1996). Adverse effects are assessed during treatment by therapists reporting on suicidal or other negative events, and by using the Negative Effects Questionnaire (Rozental et al., 2019) or a similar measure at post assessment.

Treatment effects measures

A preliminary exploration of treatment effects and assessment of a purported mediator are conducted. Primary treatment effects measure is clinical severity of diagnosis assessed using the CSR. The CSR is used at pre treatment by the therapist conducting the assessment, and at post treatment by an independent therapist who is blind to treatment condition.

In addition, treatment effects are explored in both conditions using self-report measures. General symptoms of anxiety and depression are assessed at pre and post treatment, and at each session using the Overall Anxiety Severity and Impairment Scale (OASIS; Norman et al., 2006) and the Overall Depression Severity and Impairment Scale (ODSIS; Bentley et al., 2014), respectively. These measures are used as part of the UP, and are also administered to participants in the SDP condition.

The following diagnosis-specific self-report measures, corresponding to the principal diagnosis, are responded to at pre and post treatment: the Panic Disorder Severity Scale-Self-Rated (Houck et al., 2002) for panic disorder, the Obsessive Compulsive Inventory-Revised (Foa et al., 2002) for obsessive-compulsive disorder, the Penn State Worry Questionnaire (Meyer et al., 1990) for generalized anxiety disorder, the Liebowitz Social Anxiety Scale-Self-Report (Fresco et al., 2001) for social anxiety, and the Posttraumatic Stress Disorder Checklist-5 (Blevins et al., 2015) for post-traumatic stress disorder.

At pre and post treatment, functional impairment is assessed using the World Health Organization Disability Assessment Schedule (World Health Organization, 2010), and quality of life using the EuroQol Five Dimensional Questionnaire (EuroQol Group, 1990). In addition, neuroticism, the purported mediator of the UP (Barlow et al., 2017; Sauer-Zavala et al., 2020) is assessed at pre and post treatment and at each session using the neuroticism subscale of the Eysenck Personality Questionnaire Revised - Short Form (Eysenck et al., 1985). The purpose of assessing neuroticism is to investigate adherence to multiple assessments, and to evaluate sensitivity to change.

Treatments

The UP is implemented using the Swedish translation of the published protocol (Barlow et al., 2018a, 2018b), and SDPs using evidence-based protocols recommended in clinical guidelines (e.g., prolonged exposure for post-traumatic stress disorder; Foa et al., 2007). All treatments consist of 12-18 sessions, and the number of sessions per diagnosis are matched for the UP and SDPs, so the treatment dose is the same across treatment conditions.

Procedure

Therapists receive training in the UP. Each therapist provides both the UP and SDPs in equal amounts. During treatment, therapists receive supervision in both conditions. Eligible patients are provided with oral and written study information and are invited to participate by the therapist who conduct assessment, including a diagnostic interview. Patients who consent to participate respond to self-report measures and are randomly allocated to receive the UP or an SDP. Following the last session, a diagnostic interview is conducted by an independent therapist blind to treatment condition, and participants respond to the same self-report measures.

Data analysis

Feasibility measures are analyzed primarily using descriptive statistics. Preliminary treatment effects measures are analyzed according to the intention-to-treat principle using multilevel modeling. Model-based effect sizes with 95% confidence intervals are calculated using equations suggested in Feingold (2015). In addition, based on Jacobson and Truax (1991), reliable change and clinical significance are calculated.

References

Attkison, C. C., \& Greenfield, T.K. . (1996). The client satisfaction questionnaire (CSQ) scales and the service satisfaction Scale-30 (SSS-30). In L. I. D. Sederer, B. (Ed.), Outcomes assessment in clinical practice. (pp. 120-127). Williams \& Wilkins.

Barlow, D. H., Farchione, T. J., Bullis, J. R., Gallagher, M. W., Murray-Latin, H., Sauer- Zavala, S., Bentley, K. H., Thompson-Hollands, J., Conklin, L. R., Boswell, J. F., Ametaj, A., Carl, J. R., Boettcher, H. T., \& Cassiello-Robbins, C. (2017). The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders compared with diagnosis-specific protocols for anxiety disorders: a randomized clinical trial. JAMA Psychiatry, 74(9), 875-884.

Barlow, D. H., Sauer-Zavala, S., Farchione, T. J., Murray Latin, H., Ellard, K. K., Bullis, J. R., Bentley, K. H., Boettcher, H. T., \& Cassiello-Robbins, C. (2018a). Unified protocol for transdiagnostic treatment of emotional disorders: workbook (2nd ed.). Oxford University Press.

Barlow, D. H., Farchione, T. J., Sauer-Zavala, S., Murray Latin, H., Ellard, K. K., Bullis, J. R., Bentley, K. H., Boettcher, H. T., \& Cassiello-Robbins, C. (2018b). Unified protocol for transdiagnostic treatment of emotional disorders: therapist guide (2nd ed.). Oxford University Press.

Bentley, K. H., Gallagher, M. W., Carl, J. R., \& Barlow, D. H. (2014). Development and validation of the Overall Depression Severity and Impairment Scale. Psychol Assess, 26(3), 815-830.

Bergvall, H., \& Bohman, B. (2018). The Adherence to Cognitive-Behavioral Therapy Scale: Observer Version. Unpublished.

Blackburn, I.-M., James, I. A., Milne, D. L., Baker, C., Standart, S., Garland, A., \& Reichelt, F. K. (2001). The Revised Cognitive Therapy Scale (CTS-R): psychometric properties. Behav Cogn Psychother, 29, 431-446.

Blevins, C. A., Weathers, F. W., Davis, M. T., Witte, T. K., \& Domino, J. L. (2015). The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress, 28(6), 489-498.

Boswell, J. F., Gallagher, M. W., Sauer-Zavala, S. E., Bullis, J., Gorman, J. M., Shear, M. K., Woods, S., \& Barlow, D. H. (2013). Patient characteristics and variability in adherence and competence in cognitive-behavioral therapy for panic disorder. J Consult Clin Psychol, 81(3), 443-454.

Brown, T. A., \& Barlow, D. H. (2014). Anxiety and Related Disorders Interview Schedule for DSM-5-Lifetime Version. Oxford University Press.

Devilly, G. J., \& Borkovec, T. D. (2000). Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry, 31(2), 73-86.

Eysenck, S. B., Eysenck, H. J., \& Barrett, P. (1985). A revised version of the psychoticism scale. Personality and Individual Differences, 6, 21-29.

EuroQol Group. (1990). EuroQol - a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199-208.

Feingold, A. (2015). Confidence interval estimation for standardized effect sizes in multilevel and latent growth modeling. J Consult Clin Psychol, 83(1), 157-168.

Foa, E. B., Hembree, E. A., \& Rothbaum, B. O. (2007). Prolonged exposure therapy for PTSD: emotional processing of traumatic experiences. Oxford University Press.

Foa, E. B., Huppert, J. D., Leiberg, S., Langner, R., Kichic, R., Hajcak, G., \& Salkovskis, P. M. (2002). The Obsessive-Compulsive Inventory: development and validation of a short version. Psychol Assess, 14(4), 485-496.

Fresco, D. M., Coles, M. E., Heimberg, R. G., Liebowitz, M. R., Hami, S., Stein, M. B., \& Goetz, D. (2001). The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol Med, 31(6), 1025-1035.

Houck, P. R., Spiegel, D. A., Shear, M. K., \& Rucci, P. (2002). Reliability of the self-report version of the Panic Disorder Severity Scale. Depress Anxiety, 15(4), 183-185.

Jacobson, N. S., \& Truax, P. (1991). Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol, 59(1), 12-19.

Meyer, T. J., Miller, M. L., Metzger, R. L., \& Borkovec, T. D. (1990). Development and validation of the Penn State Worry Questionnaire. Behav Res Ther, 28(6), 487-495.

Norman, S. B., Cissell, S. H., Means-Christensen, A. J., \& Stein, M. B. (2006). Development and validation of an Overall Anxiety Severity And Impairment Scale (OASIS). Depress Anxiety, 23(4), 245-249.

Rozental, A., Kottorp, A., Forsstrom, D., Mansson, K., Boettcher, J., Andersson, G., Furmark, T., \& Carlbring, P. (2019). The Negative Effects Questionnaire: psychometric properties of an instrument for assessing negative effects in psychological treatments. Behav Cogn Psychother, 47(5), 559-572.

Sauer-Zavala, S., Fournier, J. C., Jarvi Steele, S., Woods, B. K., Wang, M., Farchione, T. J., \& Barlow, D. H. (2020). Does the unified protocol really change neuroticism? Results from a randomized trial. Psychol Med, 1-10.

Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., \& Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry, 59 Suppl 20, 22- 33;quiz 34-57.

World Health Organization. (2010). Measuring Health and Disability: Manual for WHO Disability Assessment Schedule WHODAS 2.0. WHO.

03

Conditions studied

  • Panic Disorder
  • Generalized Anxiety Disorder
  • Social Anxiety Disorder
  • Obsessive-Compulsive Disorder
  • Posttraumatic Stress Disorder

Keywords

  • Transdiagnostic Treatment
  • Unified Protocol
  • Cognitive-Behavioral Therapy
  • Anxiety Disorders
  • Pilot Study
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age,
  • Being able to speak Swedish without interpreter support,
  • A principal diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, or posttraumatic stress disorder, and
  • Pharmacological treatment (if any) that is stable six weeks prior to treatment start

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of psychotic disorder, bipolar disorder, or moderate to severe substance use disorder,
  • Moderate to severe risk of suicide,
  • Psychiatric, somatic, or social problems which require other management or intervention than cognitive-behavioral therapy, and
  • Other simultaneous psychological treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Unified protocol

    Transdiagnostic cognitive-behavioral therapy focusing on emotional processes central to the development and maintenance of anxiety disorders, particularly neuroticism.

    Behavioral: Unified protocol

  • Active comparator
    Diagnosis-specific cognitive-behavioral therapy

    Cognitive-behavioral therapy specifically designed for a particular anxiety disorder as specified in evidence-based treatment protocols, which are commonly based on a specific theory or model of the development and maintenance of an anxiety disorder.

    Behavioral: Diagnosis-specific cognitive-behavioral therapy

Interventions

  • BehavioralUnified protocol

    Transdiagnostic cognitive-behavioral therapy

  • BehavioralDiagnosis-specific cognitive-behavioral therapy

    Diagnosis-specific cognitive-behavioral therapy

06

What researchers measure

Primary outcomes

  1. Feasibility measure 1

    Recruitment of participants: the number of participants per diagnosis included in the study

    Time frame: Prior to pre assessment, up to 1 month

  2. Feasibility measure 2

    Attrition: the number of participants dropping out of treatment

    Time frame: During treatment, up to 18 weeks

  3. Feasibility measure 3

    Therapist competence in and adherence to the unified protocol according to the UP Adherence and Competence Scale, and diagnosis-specific cognitive-behavioral therapy according to the Cognitive Therapy Scale-Revised

    Time frame: Prior to pre assessment, up to 6 months

  4. Feasibility measure 4

    Treatment credibility and expectancy of improvement according to the Credibility/Expectancy Questionnaire

    Time frame: During treatment Week 2

  5. Feasibility measure 5

    Treatment satisfaction according to the Client Satisfaction Questionnaire

    Time frame: At post assessment, up to 18 weeks

  6. Feasibility measure 6

    Adverse effects according to the Negative Effects Questionnaire

    Time frame: At post assessment, up to 18 weeks

Secondary outcomes

  1. Change in Clinical Severity Rating - primary outcome measure for preliminary exploration of treatment effects

    Diagnoses are assigned a dimensional clinical severity rating on a scale from 0 (no symptoms) to 8 (extremely severe symptoms), with a rating of 4 or higher (definitely disturbing or disabling) representing the clinical threshold for diagnostic criteria. Observer-assessed.

    Time frame: Change from baseline at up to 18 weeks

  2. Change in Overall Anxiety Severity and Impairment Scale

    Self-reported general anxiety

    Time frame: Change from baseline at up to 18 weeks

  3. Change in Overall Depression Severity and Impairment Scale

    Self-reported depression

    Time frame: Change from baseline at up to 18 weeks

  4. Change in Diagnosis-specific symptoms measures

    Self-reported panic symptoms, generalized anxiety symptoms, social anxiety symptoms, obsessive-compulsive symptoms, and posttraumatic stress symptoms, respectively.

    Time frame: Change from baseline at up to 18 weeks

  5. Change in World Health Organization Disability Assessment Schedule

    Self-reported functional impairment

    Time frame: Change from baseline at up to 18 weeks

  6. Change in EuroQol Five Dimensional Questionnaire

    Self-reported quality of life

    Time frame: Change from baseline at up to 18 weeks

  7. Change in Eysenck Personality Questionnaire - Revised

    Neuroticism subscale, a measure of the purported mediator of the unified protocol

    Time frame: Change from baseline at up to 18 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2026, 50 months.

Of 87 non-industry interventional studies with no phase under Panic Disorder, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 50 months is above that.

Counting every sponsor, half of 87 studies reached it within 38 months; a quarter within 21 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jun 2026 → May 2026 and completion Jun 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
Feb 21, 2022
StartActual
Mar 1, 2022
Primary completionActual
May 31, 2026was Jun 2026
CompletionActual
May 31, 2026was Jun 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • WeMind · Stockholm, Sweden
Show 1 removed
  • WeMind · Stockholm, Sweden
Nov 13, 2026
Primary completion
Jun 2026→May 31, 2026 (actual)
Nov 13, 2026
Study completion
Jun 2026→May 31, 2026 (actual)
Nov 13, 2026
Enrollment
76 (estimated)→67 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • WeMind · Stockholm, Sweden
    Show 1 removed
    • WeMind · Stockholm, Sweden
    Primary completion Jun 2026→May 31, 2026 (now actual)
    Study completion Jun 2026→May 31, 2026 (now actual)
    Enrollment 76 (estimated)→67 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05249543
Responsible party
Benjamin Bohman (Study Principal Investigator, Karolinska Institutet) — Principal investigator
First posted
Feb 21, 2022
Start date
Mar 1, 2022
Primary completion
May 31, 2026
Completion
May 31, 2026
Last update
Nov 13, 2026

Study contacts

Benjamin Bohman, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion